Data_Sheet_1_Refractory Epstein-Barr Virus (EBV)-Related Post-transplant Lymphoproliferative Disease: Cure by Combined Brentuximab Vedotin and Allogeneic EBV-Specific T-Lymphocytes.pdf
Thomas Mika
Katharina Strate
Swetlana Ladigan
Clemens Aigner
Uwe Schlegel
Iris Tischoff
Sabine Tischer-Zimmermann
Britta Eiz-Vesper
Britta Maecker-Kolhoff
Roland Schroers
10.3389/fmed.2019.00295.s001
https://frontiersin.figshare.com/articles/dataset/Data_Sheet_1_Refractory_Epstein-Barr_Virus_EBV_-Related_Post-transplant_Lymphoproliferative_Disease_Cure_by_Combined_Brentuximab_Vedotin_and_Allogeneic_EBV-Specific_T-Lymphocytes_pdf/11391657
<p>Post-transplant lymphoproliferative disease (PTLD) represents a serious complication following allogeneic hematopoietic stem cell transplantation (alloHSCT). Previously, survival rates of PTLD have improved due to the introduction of rituximab. However, reports on curative management of refractory PTLD are scarce. Today, there is no consensus how to treat rituximab-refractory PTLD, especially in highly aggressive disease. Here, we describe successful management of refractory EBV-associated PTLD, specifically DLBCL, with combined brentuximab vedotin and third-party EBV-specific T-cells in a multidisciplinary treatment approach.</p>
2019-12-18 04:12:04
PTLD
alloHSCT
aggressive lymphoma
brentuximab vedotin (BV)
third-party EBV-specific T-lymphocytes